Wide Ranks

BRTX

BioRestorative Therapies, Inc.

1.48

Top Statistics
Market Cap 10 M Forward PE -1.72 Revenue Growth 660.90 %
Current Ratio 2.95 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.2340 Enterprise / Revenue -7.40 Price To Sales Trailing12 Months 27.17
Profitability
Profit Margins 0.00 % Operating Margins -979.02 %
Balance Sheet
Total Cash 13 M Total Cash Per Share 1.89 Total Debt 42414
Total Debt To Equity 0.4240 Current Ratio 2.95 Book Value Per Share 1.44
All Measures
Short Ratio 248.00 % Message Board Id finmb_58274944 Shares Short Prior Month 46226
Return On Equity -0.1712 City Melville Uuid 2c74d2b3-1dc4-3810-9931-a8f44a470865
Previous Close 1.50 First Trade Date Epoch Utc 1 B Book Value 1.44
Total Debt 42414 Volume 14348 Price To Book 1.03
Last Split Date 1 B Fifty Two Week Low 1.03 Total Cash Per Share 1.89
Total Revenue 377000 Shares Short Previous Month Date 1 B Target Median Price 13.00
Max Age 86400 Recommendation Mean 2.00 Sand P52 Week Change 0.3133
Operating Margins -979.02 % Target Mean Price 13.00 Net Income To Common -1953474
Short Percent Of Float 0.0132 Implied Shares Outstanding 7 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 28870 Average Volume10days 28870
Total Cash 13 M Next Fiscal Year End 1 B Revenue Per Share 0.0550
Held Percent Insiders 0.2632 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.50 Target Low Price 8.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.61 Open 1.49
Free Cashflow -2403903 State NY Dividend Yield 0.00 %
Return On Assets -0.5324 Time Zone Short Name EST Trailing Eps -2.38
Day Low 1.48 Address1 40 Marcus Drive Shares Outstanding 6 M
Price Hint 4 Target High Price 18.00 Website https://www.biorestorative.com
52 Week Change -0.2291 Average Volume 26200 Forward Eps -1.71
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 289.30 %
Last Split Factor 1:4000 Regular Market Day High 1.55 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 0.4240 Fifty Two Week High 3.67
Day High 1.55 Shares Short 74437 Regular Market Open 1.49
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue -7.40
Revenue Growth 660.90 % Shares Percent Shares Out 0.0108 Operating Cashflow -7472161
Currency USD Time Zone Full Name America/New_York Market Cap 10 M
Is_nasdaq_100 False Zip 11747 Quote Type EQUITY
Industry Biotechnology Long Name BioRestorative Therapies, Inc. Regular Market Day Low 1.48
Held Percent Institutions 0.1374 Current Price 1.48 Address2 Suite 1
Enterprise To Ebitda 0.2340 Financial Currency USD Current Ratio 2.95
Gross Margins 93.44 % Industry Disp Biotechnology Number Of Analyst Opinions 2
Country United States Float Shares 5 M Two Hundred Day Average 1.52
Enterprise Value -2789293 Price To Sales Trailing12 Months 27.17 Forward PE -1.72
Regular Market Volume 14348 Ebitda -11904334 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.

The company develops programs relate to the treatment of disc/spine disease and metabolic disorders.

Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.

The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body.

BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co.

, Ltd.

; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania.

The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011.

BioRestorative Therapies, Inc. is based in Melville, New York.